New dialyser aims to cut blood thinner risks for kidney patients

NCT ID NCT06281028

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two dialysis filters, SOLACEA-H and HYDROLINK-NVU, to see if SOLACEA-H can allow dialysis sessions with less or no blood thinner (heparin). The trial involves 20 adults who have been on dialysis for at least 3 months and are medically stable. Each participant will try both filters in sequence, gradually reducing blood thinner doses to find the minimum effective amount.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SOLACEA-H dialyser

What this could lead to

If successful, this dialyser could allow safer dialysis for patients at high risk of bleeding by reducing the need for blood thinners.

What could go wrong

This is a small, early-stage study with only 20 participants, so results may not apply to all dialysis patients. The device may not work as well as expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Privé La Louvière

    Lille, 59800, France